China FDA Proposes Sweeping Action On Drug Approvals, Poor Quality Submissions
This article was originally published in SRA
The China Food and Drug Administration has proposed a series of drastic actions to reduce the backlog of drug applications and rapidly push forward planned reforms to its regulatory review system.
You may also be interested in...
CanSino's COVID-19 vaccine is on the cusp of a formal approval in China, as is another candidate from state-owned Sinopharm. Meanwhile, China is shipping millions of doses around the world.
While global vaccine heavyweights Merck & Co, Sanofi and GSK are so far not faring so well to successfully develop a vaccine for COVID-19, smaller players are stepping up. That's especially true for segmented markets such as China.
A WHO team concludes a high-profile investigation in Wuhan, where the first coronavirus cases surfaced over a year ago, while a single-dose vaccine from China's CanSino is on the way.